Shattuck Labs (STTK) Cash from Financing Activities (2019 - 2026)
Shattuck Labs' (STTK) quarterly Cash from Financing Activities came in at $25.8 million in Q1 2026, up 45368.42% year-on-year from N/an in Q1 2025, and up 19155.97% on a QoQ basis from $134000.0 in Q4 2025.
Shattuck Labs (STTK) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Shattuck Labs (STTK) has 8 years of Cash from Financing Activities data on file, last reported at $25.8 million in Q1 2026.
- On a quarterly basis, Cash from Financing Activities rose 45368.42% year-over-year to $25.8 million in Q1 2026; TTM through Mar 2026 was $70.4 million, a 7606.13% increase from a year earlier, with the FY2025 full-year figure at $44.6 million, up 5563.79% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $25.8 million, up from $134000.0 in the prior quarter.
- Over the last five years, Cash from Financing Activities for STTK reached as high as $48.6 million in Q4 2023 and fell as low as -$184000.0 in Q1 2024.
- Historically, Cash from Financing Activities has averaged $8.6 million across 5 years, with a median of $30000.0 in 2022.
- Across the five-year window, Cash from Financing Activities slumped 100.15% in 2024 and surged 193365.22% in 2025, its largest moves.
- Year by year, Cash from Financing Activities stood at $27000.0 in 2022, then soared by 179759.26% to $48.6 million in 2023, then tumbled by 100.15% to -$72000.0 in 2024, then jumped by 286.11% to $134000.0 in 2025, then jumped by 19155.97% to $25.8 million in 2026.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were $25.8 million in Q1 2026, $134000.0 in Q4 2025, and $44.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 53,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 68.63 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 238.74 Mn |
| 10 | Shattuck Labs | 831.66 Mn | 831.66 Mn | - | 25.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25.80 Mn |
| Mar 31, 2026 | 25.80 Mn |
| Dec 31, 2025 | 134,000.00 |
| Dec 31, 2025 | 134,000.00 |
| Sep 30, 2025 | 44.50 Mn |
| Sep 30, 2025 | 44.50 Mn |
| Mar 31, 2025 | -57,000.00 |
| Mar 31, 2025 | -57,000.00 |
| Dec 31, 2024 | -72,000.00 |
| Dec 31, 2024 | -72,000.00 |
| Sep 30, 2024 | 23,000.00 |
| Sep 30, 2024 | 23,000.00 |
| Jun 30, 2024 | 1.02 Mn |
| Jun 30, 2024 | 1.02 Mn |
| Mar 31, 2024 | -184,000.00 |
| Mar 31, 2024 | -184,000.00 |
| Dec 31, 2023 | 48.56 Mn |
| Dec 31, 2023 | 48.56 Mn |
| Sep 30, 2023 | 21,000.00 |
| Sep 30, 2023 | 21,000.00 |